Aquestive Therapeutics Reiterates Expected Timing For Anaphylm NDA Filing For Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics has reiterated that it expects to file the New Drug Application (NDA) for Anaphylm in Q1 2025.
August 14, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics has reiterated its plan to file the NDA for Anaphylm in Q1 2025, which could be a significant milestone for the company.
The confirmation of the NDA filing timeline for Anaphylm is a positive development for Aquestive Therapeutics, as it indicates progress in their product pipeline. This could boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100